After a difficult season that has seen two deaths linked to Sarepta Therapeutics’ Duchenne muscular dystrophy treatment Elevidys, the Cambridge, Massachusetts–based biotech is letting go of more than a third of its workforce and adding a black box warning for acute liver injury and acute liver failure to the gene therapy. In a July 16 announcement, Sarepta revealed it will part with around 500 employees after a strategic review and focus its pipeline on “high-impact programs, prioritizing potentially best-in-class siRNA platform assets.” These include programs for facioscapulohumeral muscular dystrophy, idiopathic pulmonary fibrosis and Huntington’s disease.
